Aptose Biosciences Inc logo

APTO - Aptose Biosciences Inc Share Price

$4.16 0.0  1.0%

Last Trade - 24/02/21

Small Cap
Market Cap £262.7m
Enterprise Value £194.6m
Revenue £n/a
Position in Universe 3791st / 6714
Unlock APTO Revenue
Relative Strength (%)
1m -6.66%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -54.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 3.27
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, AptoseBiosciences Inc revenues was not reported. Net lossdecreased 9% to $26.3M. Lower net loss reflects Stock-basedcompensation decrease of 44% to $1.8M (expense),Stock-based compensation decrease of 54% to $474K (expense), Interest income increase from $283K to $574K (income).Basic Earnings per Share excluding Extraordinary Itemsincreased from -$0.86 to -$0.52.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


APTO Revenue Unlock APTO Revenue

Net Income

APTO Net Income Unlock APTO Revenue

Normalised EPS

APTO Normalised EPS Unlock APTO Revenue

PE Ratio Range

APTO PE Ratio Range Unlock APTO Revenue

Dividend Yield Range

APTO Dividend Yield Range Unlock APTO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
APTO EPS Forecasts Unlock APTO Revenue
Profile Summary

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated November 1, 2006
Public Since June 4, 1993
No. of Shareholders: 33
No. of Employees: 31
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market (Dual Listing)
Shares in Issue 88,861,737
Free Float (0.0%)
Eligible for
APTO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for APTO
Upcoming Events for APTO
Frequently Asked Questions for Aptose Biosciences Inc
What is the Aptose Biosciences Inc share price?

As of 24/02/21, shares in Aptose Biosciences Inc are trading at $4.16, giving the company a market capitalisation of £262.7m. This share price information is delayed by 15 minutes.

How has the Aptose Biosciences Inc share price performed this year?

Shares in Aptose Biosciences Inc are currently trading at $4.16 and the price has moved by -49.45% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aptose Biosciences Inc price has moved by -59.21% over the past year.

What are the analyst and broker recommendations for Aptose Biosciences Inc?

Of the analysts with advisory recommendations for Aptose Biosciences Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aptose Biosciences Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Aptose Biosciences Inc next release its financial results?

Aptose Biosciences Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Aptose Biosciences Inc dividend yield?

Aptose Biosciences Inc does not currently pay a dividend.

Does Aptose Biosciences Inc pay a dividend?

Aptose Biosciences Inc does not currently pay a dividend.

When does Aptose Biosciences Inc next pay dividends?

Aptose Biosciences Inc does not currently pay a dividend.

How do I buy Aptose Biosciences Inc shares?

To buy shares in Aptose Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aptose Biosciences Inc?

Shares in Aptose Biosciences Inc are currently trading at $4.16, giving the company a market capitalisation of £262.7m.

Where are Aptose Biosciences Inc shares listed? Where are Aptose Biosciences Inc shares listed?

Here are the trading details for Aptose Biosciences Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: APTO
What kind of share is Aptose Biosciences Inc?

Based on an overall assessment of its quality, value and momentum, Aptose Biosciences Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aptose Biosciences Inc share price forecast 2021?

Shares in Aptose Biosciences Inc are currently priced at $4.16. At that level they are trading at 0.112% discount to the analyst consensus target price of 0.00.

Analysts covering Aptose Biosciences Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.674790657 for the next financial year.

How can I tell whether the Aptose Biosciences Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aptose Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been -26.17%. At the current price of $4.16, shares in Aptose Biosciences Inc are trading at -25.79% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aptose Biosciences Inc PE Ratio?

We were not able to find PE ratio data for Aptose Biosciences Inc.

Who are the key directors of Aptose Biosciences Inc?

Aptose Biosciences Inc's management team is headed by:

Denis Burger - LED
Mark Vincent - IND
William Rice - CHM
Gregory Chow - CFO
Erich Platzer - IND
Caroline Loewy - IND
Carol Ashe - IND
Jotin Marango - SVP
Rafael Bejar - SVP
Who are the major shareholders of Aptose Biosciences Inc?

Here are the top five shareholders of Aptose Biosciences Inc based on the size of their shareholding:

OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 9.04% (8.03m shares)
DRW Securities, LLC Investment Advisor
Percentage owned: 8.98% (7.98m shares)
Nantahala Capital Management, LLC Hedge Fund
Percentage owned: 8.18% (7.27m shares)
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 4.42% (3.93m shares)
Abramson (Herbert) Individual Investor
Percentage owned: 4.15% (3.69m shares)
Similar to APTO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.